Together, these data suggest that L1CAM is required for maintaining the growth and survival of CD133+ glioma cells both in vivo and in vitro, and L1CAM may represent a GSC specific therapeutic target for improving the treatment of glioblastoma and possibly other brain tumors. The gene discussed is PROM1; the disease is glioblastoma.